Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 domain containing kinase binding protein 1 (SH3KBP1, also called CIN85) is an adapter/scaffold protein encoded by the human SH3KBP1 gene. It contains multiple Src homology 3 (SH3) domains, enabling it to mediate protein-protein interactions in diverse cellular processes. SH3KBP1 is essential for clathrin-dependent endocytosis, regulation of receptor tyrosine kinase pathways (like EGFR and MET), cytoskeletal rearrangement, cell adhesion, immune cell activation, and regulation of apoptotic signaling. It interacts with CBL and endophilins to promote receptor internalization, modulates TNF-alpha-induced apoptosis, and is implicated in cancer, immunodeficiency, and neurological disorders. No drugs directly target SH3KBP1, but its pathway involvement makes it a significant research target in oncology and immunology.
Drugs targeting upstream or downstream pathways (e.g., EGFR inhibitors) may exert effects modulated by SH3KBP1, especially in receptor degradation or signal attenuation. No direct mechanisms for SH3KBP1-targeted drugs documented to date
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH3 domain containing kinase binding protein 1 (SH3KBP1).